Pharmaceutical Technology Europe-03-01-2012

The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.

Traditionally more prevalent in less industrialised regions, counterfeit medicines are now more frequently entering the heavily regulated supply chains of EU countries.

Boehringer Ingelheim's Heribert Häusler tells us about parametric release and real-time testing.

In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.

Regulatory bodies, standard-setting organizations, and industry seek to tackle the problem of counterfeit drugs and securing the flow of pharma ingredients.

The evolving bio/pharmaceutical business model poses risk for CMOs.

The authors describe a new assembly for bulk and final drug product filling operations.